# A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

> **NCT04749394** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 42 (estimated)

## Conditions studied

- Locally Advanced Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Camrelizumab, PD-1 monoclonal antibody
- **DRUG:** Apatinib, VEGFR2 antibody

## Key facts

- **NCT ID:** NCT04749394
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-17
- **Primary completion:** 2025-01
- **Final completion:** 2025-06
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2022-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04749394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04749394, "A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04749394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*